| Literature DB >> 31620675 |
Weilong Lin1, Ke-Feng Zhang1, Olivier Baudoin1.
Abstract
β2- and β3-Amino acids are important chiral building blocks for the design of new pharmaceuticals and peptidomimetics. Here we report a straightforward regio- and enantiodivergent access to these compounds using a one-pot reaction composed of sparteine-mediated enantioselective lithiation of a Boc-1,3-oxazinane, transmetallation to zinc and direct or migratory Negishi coupling with an organic electrophile. The regioselectivity of the Negishi coupling was highly ligand-controlled and switchable to obtain the C4- or the C5-functionalized product exclusively. High enantioselectivities were achieved on a broad range of examples, and a catalytic version in chiral diamine was developed using the (+)-sparteine surrogate. Selected C4- and C5-functionalized Boc-1,3-oxazinanes were subsequently converted to highly enantio-enriched β2- and β3-amino acids with the (R) or (S) configuration, depending on the sparteine enantiomer employed in the lithiation step.Entities:
Year: 2019 PMID: 31620675 PMCID: PMC6795538 DOI: 10.1038/s41929-019-0336-1
Source DB: PubMed Journal: Nat Catal
Fig. 1Examples of natural products and active pharmaceutical ingredients containing β2- and β3-amino acids.
Fig. 2Lithiation/Negishi coupling of cyclic Boc-amines. a, The Negishi coupling of α-zincated Boc-piperidine 1 furnishes racemic C-2 (2) and C-3 (3) arylated products with good site-selectivity in the presence of appropriate phosphine ligands L. b, Enantioselective lithiation and direct Negishi coupling is effective for Boc-pyrrolidine, but not for Boc-piperidine. c, This work: design of a site- and enantioselective functionalization of Boc-1,3-oxazinanes and application to the synthesis of β-amino acids. Boc = tert-butyloxycarbonyl; TMEDA = N,N,N′,N′-tetramethylethylenediamine; dba = dibenzylideneacetone; NN* = chiral diamine; sp = sparteine.
Effect of selected parameters on the arylation of Boc-1,3-oxazinanes
| Entry | Z | Reactant | Diamine | Ligand | 8/9[ | Product | Yield (%)[ | e.r.[ |
|---|---|---|---|---|---|---|---|---|
| 1[ | Me | TMEDA | >98:2 | 54 | – | |||
| 2[ | Me | (+)-sp | >98:2 | 53 | 75:25 | |||
| 3[ | Et | (+)-sp | >98:2 | 51 | 95:5 | |||
| 4[ | Et | (+)-sp surrogate | >98:2 | 46 | 91:9 | |||
| 5[ | (+)-sp | >98:2 | 30 | 94:6 | ||||
| 6[ | Et | (+)-sp | >98:2 | 61 | 97:3 | |||
| 7a | Me | TMEDA | <2:98 | 65 | – | |||
| 8 | Me | (+)-sp | <2:98 | 51 | 77.5:22.5 | |||
| 9 | Et | (+)-sp | <2:98 | 48 | 97:3 | |||
| 10 | Et | (+)-sp surrogate | <2:98 | 89 | 94:6 | |||
| 11[ | (+)-sp | <2:98 | 72 | 96.5:3.5 | ||||
| 12 | –(CH2)4– | (+)-sp | <2:98 | 23 | 85:15 | |||
Reaction conditions unless otherwise stated: 7 (1.0 equiv), s-BuLi (1.2 equiv), diamine (1.2 equiv), Et2O, –78 °C, 8 h, then ZnCl2/THF (1.2 equiv), –78→20 °C, 1 h, then removal of volatiles, then PhBr (0.7 equiv), Pd2dba3 (2.5 mol%), ligand (5 mol%), toluene, 80 °C, 17-24 h.
Measured by GCMS or 1H NMR analysis of the crude reaction mixture.
Yield of the isolated product.
Determined by HPLC on a chiral stationary phase.
Cross-coupling step performed at 60 °C instead of 80 °C.
Using Zn(OAc)2 instead of ZnCl2 and PhONf instead of PhBr.
Conditions employed in Fig. 3-4. Nf = SO2(CF2)3CF3.
Fig. 3Trapping experiments. TFA = trifluoroacetic acid. X = Cl or OAc, Y = Br or ONf (see Table 1). The deuterium contents were measured by 1H NMR. Enantiomeric ratio of the mixtures of isotopomers, determined by HPLC on a chiral stationary phase.
Fig. 4Scope of the C4- and C5-functionalization of Boc-1,3-oxazinanes. Reaction conditions: see Table 1, entries 6 (C4-functionalization) and 11 (C5-functionalization). E.r. values were determined by HPLC on a chiral stationary phase, either directly or on the Boc-protected aminoalcohol after cleavage of the aminal. The reference racemic products were synthesized using TMEDA instead of sp. Using (–)-sp instead of (+)-sp. Using L as the ligand. Isolated as an inseparable 77:23 mixture of C5- and C6-isomers. Performed on gram scale; 85% of (–)-sp was recovered.
Fig. 5Development of proof of concept catalytic enantioselective C4- and C5-arylations. Reaction conditions: 7 (1.0 equiv), s-BuLi (1.2 equiv), (+)-sp surrogate (0.3 equiv), diisopropylbispidine (1.3 equiv), Et2O, –78 °C, 8 h, then Zn(OAc)2 (C4-arylation) or ZnCl2 (C5-arylation), THF (1.2 equiv), –78→20 °C, 1 h, then removal of volatiles, then PhBr (0.7 equiv), Pd2dba3 (2.5 mol%), ligand (5 mol%), toluene, 80 °C, 17 h. Using (+)-sp instead of the (+)-sp surrogate.
Fig. 6Application to the synthesis of β Reaction conditions: 1. TFA, THF, 20 °C. 2. Method A: RuCl3 (5 mol%), NaIO4 (3 equiv), MeCN/H2O, 20 °C. Method B: TEMPO (20 mol%), PIDA (2 equiv), CH2Cl2/H2O, 20 °C. (S) enantiomers were obtained with (+)-sp and (R) enantiomers with (–)-sp. Yields in parentheses refer to the overall sequence from Boc-1,3-oxazinanes 7b-c. The e.r. were determined after derivatization to the corresponding methyl esters. Obtained using method A. Obtained using method B. Thermal ellipsoids shown at 50 % probability. TEMPO = (2,2,6,6-tetramethylpiperidin-1-yl)oxyl; PIDA = (diacetoxyiodo)benzene.